Which has preferable earnings & valuation, ORIC or ALXO?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A ALX Oncology N/A N/A -$101.69M -$1.49 N/A

Is ORIC or ALXO more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% ALX Oncology N/A -124.06% -85.57%

Does the media refer more to ORIC or ALXO?

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than ALX Oncology. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for ALX Oncology. Oric Pharmaceuticals' average media sentiment score of 0.00 beat ALX Oncology's score of -0.28 indicating that Oric Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ALXO or SANA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is ALXO or SANA more profitable?

Sana Biotechnology's return on equity of -108.01% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Sana Biotechnology N/A -108.01% -40.68%

Does the media prefer ALXO or SANA?

In the previous week, Sana Biotechnology had 3 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for ALX Oncology. Sana Biotechnology's average media sentiment score of 0.19 beat ALX Oncology's score of -0.28 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALXO or PHAR?

In the previous week, Pharming Group had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Pharming Group and 1 mentions for ALX Oncology. Pharming Group's average media sentiment score of 0.66 beat ALX Oncology's score of -0.28 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ALXO or KURA?

In the previous week, Kura Oncology had 12 more articles in the media than ALX Oncology. MarketBeat recorded 13 mentions for Kura Oncology and 1 mentions for ALX Oncology. Kura Oncology's average media sentiment score of -0.15 beat ALX Oncology's score of -0.28 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ALX Oncology 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

ALX Oncology (ALXO) Competitors

$1.57 +0.03 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.00 (+0.32%)

As of 04:10 PM Eastern

Compare

ALXO vs. ORIC, SANA, PHAR, KURA, and ABUS

Should you buy ALX Oncology stock or one of its competitors? MarketBeat compares ALX Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ALX Oncology include Oric Pharmaceuticals (ORIC), Sana Biotechnology (SANA), Pharming Group (PHAR), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does ALX Oncology compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, Oric Pharmaceuticals had 1 more articles in the media than ALX Oncology. MarketBeat recorded 2 mentions for Oric Pharmaceuticals and 1 mentions for ALX Oncology. Oric Pharmaceuticals' average media sentiment score of 0.00 beat ALX Oncology's score of -0.28 indicating that Oric Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

Oric Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

Oric Pharmaceuticals' return on equity of -35.33% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
ALX Oncology	N/A	-124.06%	-85.57%

Oric Pharmaceuticals currently has a consensus price target of $19.36, suggesting a potential upside of 157.15%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 192.99%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Oric Pharmaceuticals beats ALX Oncology on 8 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Sana Biotechnology?

ALX Oncology (NASDAQ:ALXO) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.

ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

In the previous week, Sana Biotechnology had 3 more articles in the media than ALX Oncology. MarketBeat recorded 4 mentions for Sana Biotechnology and 1 mentions for ALX Oncology. Sana Biotechnology's average media sentiment score of 0.19 beat ALX Oncology's score of -0.28 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sana Biotechnology's return on equity of -108.01% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Sana Biotechnology	N/A	-108.01%	-40.68%

ALX Oncology presently has a consensus price target of $4.60, indicating a potential upside of 192.99%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 253.16%. Given Sana Biotechnology's higher probable upside, analysts plainly believe Sana Biotechnology is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sana Biotechnology is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Summary

Sana Biotechnology beats ALX Oncology on 9 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Pharming Group?

ALX Oncology (NASDAQ:ALXO) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Pharming Group has a net margin of 3.30% compared to ALX Oncology's net margin of 0.00%. Pharming Group's return on equity of 4.64% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Pharming Group	3.30%	4.64%	2.55%

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 192.99%. Pharming Group has a consensus price target of $38.33, suggesting a potential upside of 199.48%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ALX Oncology has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

Pharming Group has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Pharming Group	$376.13M	2.40	$2.85M	$0.16	80.00

In the previous week, Pharming Group had 2 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for Pharming Group and 1 mentions for ALX Oncology. Pharming Group's average media sentiment score of 0.66 beat ALX Oncology's score of -0.28 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pharming Group beats ALX Oncology on 10 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Kura Oncology?

ALX Oncology (NASDAQ:ALXO) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

In the previous week, Kura Oncology had 12 more articles in the media than ALX Oncology. MarketBeat recorded 13 mentions for Kura Oncology and 1 mentions for ALX Oncology. Kura Oncology's average media sentiment score of -0.15 beat ALX Oncology's score of -0.28 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ALX Oncology has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Kura Oncology	$67.48M	11.26	-$278.67M	-$3.35	N/A

98.0% of ALX Oncology shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ALX Oncology has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. ALX Oncology's return on equity of -124.06% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Kura Oncology	-411.19%	-141.95%	-43.28%

ALX Oncology has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 192.99%. Kura Oncology has a consensus price target of $25.58, suggesting a potential upside of 198.87%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Kura Oncology is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

ALX Oncology beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Arbutus Biopharma?

ALX Oncology (NASDAQ:ALXO) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

In the previous week, ALX Oncology had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 1 mentions for ALX Oncology and 0 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.00 beat ALX Oncology's score of -0.28 indicating that Arbutus Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
ALX Oncology	Neutral
Arbutus Biopharma	Neutral

ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to ALX Oncology's net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arbutus Biopharma has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Arbutus Biopharma	$14.08M	59.49	-$33.50M	$0.83	5.11

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ALX Oncology presently has a consensus price target of $4.60, indicating a potential upside of 192.99%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 17.92%. Given ALX Oncology's stronger consensus rating and higher possible upside, equities analysts plainly believe ALX Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Arbutus Biopharma beats ALX Oncology on 9 of the 15 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$207.23M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	-1.05	18.61	23.92	23.74
Price / Sales	N/A	298.40	507.55	107.95
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.27	8.04	10.28	6.78
Net Income	-$101.69M	$23.89M	$3.57B	$337.51M
7 Day Performance	-12.78%	-5.97%	-1.43%	-2.72%
1 Month Performance	-24.52%	2.78%	3.27%	1.87%
1 Year Performance	171.16%	36.26%	23.37%	26.60%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	3.4436 of 5 stars	$1.57 +1.9%	$4.60 +193.0%	+166.0%	$207.23M	N/A	N/A	40
ORIC Oric Pharmaceuticals	1.9777 of 5 stars	$8.98 +6.3%	$19.36 +115.6%	-19.5%	$929.59M	N/A	N/A	80	Analyst Forecast High Trading Volume
SANA Sana Biotechnology	3.4473 of 5 stars	$3.21 -2.7%	$9.50 +196.0%	-5.6%	$918.36M	N/A	N/A	380	Analyst Downgrade Gap Up
PHAR Pharming Group	3.8941 of 5 stars	$13.10 +0.8%	$38.33 +192.6%	+5.6%	$917.42M	$376.13M	81.88	280
KURA Kura Oncology	2.1623 of 5 stars	$9.03 -11.5%	$25.90 +186.8%	+29.9%	$905.50M	$71.64M	N/A	130

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. ORIC, SANA, PHAR, KURA, and ABUS

How does ALX Oncology compare to Oric Pharmaceuticals?

Summary

How does ALX Oncology compare to Sana Biotechnology?

Summary

How does ALX Oncology compare to Pharming Group?

Summary

How does ALX Oncology compare to Kura Oncology?

Summary

How does ALX Oncology compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. ORIC, SANA, PHAR, KURA, and ABUS

How does ALX Oncology compare to Oric Pharmaceuticals?

Does the media refer more to ORIC or ALXO?

Which has preferable earnings & valuation, ORIC or ALXO?

Which has more volatility and risk, ORIC or ALXO?

Is ORIC or ALXO more profitable?

Do analysts prefer ORIC or ALXO?

Do institutionals & insiders believe in ORIC or ALXO?

Summary

How does ALX Oncology compare to Sana Biotechnology?

Which has more volatility and risk, ALXO or SANA?

Does the media prefer ALXO or SANA?

Do insiders and institutionals believe in ALXO or SANA?

Is ALXO or SANA more profitable?

Do analysts recommend ALXO or SANA?

Which has higher valuation & earnings, ALXO or SANA?

Summary

How does ALX Oncology compare to Pharming Group?

Is ALXO or PHAR more profitable?

Do analysts rate ALXO or PHAR?

Do insiders and institutionals hold more shares of ALXO or PHAR?

Which has more volatility & risk, ALXO or PHAR?

Which has stronger valuation and earnings, ALXO or PHAR?

Does the media prefer ALXO or PHAR?

Summary

How does ALX Oncology compare to Kura Oncology?

Does the media refer more to ALXO or KURA?

Which has higher earnings & valuation, ALXO or KURA?

Do insiders & institutionals believe in ALXO or KURA?

Is ALXO or KURA more profitable?

Which has more risk and volatility, ALXO or KURA?

Do analysts rate ALXO or KURA?

Summary

How does ALX Oncology compare to Arbutus Biopharma?

Does the media prefer ALXO or ABUS?

Which has more volatility and risk, ALXO or ABUS?

Is ALXO or ABUS more profitable?

Which has higher earnings and valuation, ALXO or ABUS?

Do institutionals and insiders have more ownership in ALXO or ABUS?

Do analysts recommend ALXO or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools